Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/4/2020
SIETES contiene 92957 citas

 
 
 1 a 20 de 7714 siguiente >>
Presentar resultados
Seleccionar todas
2.Tiene citas relacionadas Cita con resumen
Dyer O. Cochrane reviewer sues Roche for claiming Tamiflu could slow flu pandemic. BMJ 2020;368:31 de enero. [Ref.ID 103541]
3. Cita con resumen
Hripcsak G, Suchard MA, Shea S, Chen RJ, You SC, Pratt N, Madigan D, Krumholz HM, Ryan PB, Schuemie MJ. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med 2020:17 de febrero. [Ref.ID 103537]
4. Cita con resumen
Sys J, Van Cleynenbreugel S, Deschodt M, Van der Linden L, Tournoy J. Efficacy and safety of non-benzodiazepine and non-Z-drug hypnotic medication for insomnia in older people: a systematic literature review. Eur J Clin Pharmacol 2020;76:marzo. [Ref.ID 103530]
5. Cita con resumen
Butler CC, van der Velden AW, Bongard E, Saville BR, Holmes J, Coenen S, Cook J, et al.. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet 2020;395:4 de enero. [Ref.ID 103501]
8. Cita con resumen
Healy D, Mangin D. Clinical judgments, not algorithms, are key to patient safety. BMJ 2019;367:2 de octubre. [Ref.ID 103204]
10.Enlace a cita original Cita con resumen
Ross JDC, Brittain C, Cole M, Dewsnap C, Harding J, Hepburn T, Jackson L, Keogh M, Lawrence T, Montgomery AA, Roberts TE, Sprange K, Tan W, Thandi S, Wilson J, Duley L, on behalf of the G-ToG trial team. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet 2019:2 de mayo. [Ref.ID 103140]
11.Enlace a cita original Cita con resumen
Garmendia CA, Gorra LN, Rodríguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses. The example of the apixaban trials. JAMA Intern Med 2019;179:4 de marzo. [Ref.ID 103094]
12.Enlace a cita original Cita con resumen
Musso G, Gambino R, Cassader M, Paschetta E. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2019;365:9 de abril. [Ref.ID 103085]
13. Cita con resumen
Busse JW, Wang L, Kamaleldin M, Craigie S, Riva JJ, Montoya L, et al.. Opioids for chronic noncancer pain. A systematic review and meta-analysis. JAMA 2018;320:18 de diciembre. [Ref.ID 102914]
14.Enlace a cita originalTiene citas relacionadas Cita con resumen
Hengartner MP. What is the threshold for a clinical minimally important drug effect?. BMJ Evidence-Based Medicine 2018;23:21 de noviembre. [Ref.ID 102912]
15.Enlace a cita originalTiene citas relacionadas Cita con resumen
Furukawa TA, Maruo K, Noma H, Tanaka S, Imai H, Shinohara K, Ikeda K, Yamawaki S, Levine SZ, Goldberg Y, Leucht S, Cipriani A. Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. Acta Psychiatr Scand 2018;137:junio. [Ref.ID 102911]
16. Cita con resumen
Anónimo. Létermovir et prévention d'une réactivation du cytomégalovirus. Prescrire 2018;38:895-8. [Ref.ID 102905]
17. Cita con resumen
Anónimo. Ocrélizumab et sclérose en plaques. Prescrire 2018;38:890-2. [Ref.ID 102904]
18.Enlace a cita original Cita con resumen
Girard TD , Exline MC , Carson SS , Hough CL , Rock P , Gong MN , Douglas IS , Malhotra A , Owens RL , Feinstein DJ , Khan B , Pisani MA , Hyzy RC , Schmidt GA , Schweickert WD , Hite RD , Bowton DL , Masica AL , Thompson JL , Chandrasekhar R , Pun BT , Strength C , Boehm LM , Jackson JC , Pandharipande PP , Brummel NE , Hughes CG , Patel MB , Stollings JL , Bernard GR , Dittus RS , Ely EW , for the MIND-USA Investigators. Haloperidol and ziprasidone for treatment of delirium in vritical illness. N Engl J Med 2018;379:22 de octubre. [Ref.ID 102838]
19.Enlace a cita original Cita con resumen
Moore TJ, Hanzhe Z, Anderson G, Alexander C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med 2018:24 de septiembre. [Ref.ID 102831]
20.Enlace a cita original Cita con resumen
Puthumana J, Wallach JD, Ross JS. Clinical trial evidence supporting FDA approval of drugs granted breakthrough therapy designation. JAMA 2018;319:17 de julio. [Ref.ID 102793]
Seleccionar todas
 
 1 a 20 de 7714 siguiente >>